Sequential-cmab009 (** No known brand names or generic equivalents identified. **)
Other Medications
Description
CMAB009 is an experimental medicine being studied for colorectal cancer. It is a type of monoclonal antibody, which is a lab-made protein designed to target specific substances in the body. In this case, CMAB009 targets the Epidermal Growth Factor Receptor (EGFR), a protein found on the surface of some cancer cells. The trial you are asking about (NCT01550055) investigated whether adding CMAB009 to the chemotherapy drug irinotecan would be more effective than irinotecan alone in patients with metastatic colorectal cancer (cancer that has spread) whose tumors have a specific characteristic: they do not have a KRAS mutation (KRAS wild-type). This trial was designed to see if the combination improved response rates and prolonged survival compared to irinotecan alone. CMAB009 is similar in structure to another drug called cetuximab, but it has some differences in how it's made.
Mechanism of Action
CMAB009 is a monoclonal antibody. It works by specifically binding to the EGFR protein on the surface of certain cancer cells. By attaching to EGFR, CMAB009 may block signals that tell the cancer cells to grow and divide. This can potentially slow down or stop the growth of the cancer. The specific trial (NCT01550055) focused on patients with KRAS wild-type metastatic colorectal cancer, suggesting that EGFR targeting might be particularly relevant for this subgroup.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.